Canopy Growth (CGC) Competitors $1.38 -0.01 (-0.72%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CGC vs. CRON, DNTH, AVBP, EOLS, ANAB, ABUS, XERS, CDXC, KALV, and ARVNShould you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Cronos Group (CRON), Dianthus Therapeutics (DNTH), ArriVent BioPharma (AVBP), Evolus (EOLS), AnaptysBio (ANAB), Arbutus Biopharma (ABUS), Xeris Biopharma (XERS), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. Canopy Growth vs. Cronos Group Dianthus Therapeutics ArriVent BioPharma Evolus AnaptysBio Arbutus Biopharma Xeris Biopharma ChromaDex KalVista Pharmaceuticals Arvinas Cronos Group (NASDAQ:CRON) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings. Does the MarketBeat Community believe in CRON or CGC? Cronos Group received 444 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Canopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% Do analysts rate CRON or CGC? Cronos Group presently has a consensus price target of $3.50, suggesting a potential upside of 86.17%. Canopy Growth has a consensus price target of $2.00, suggesting a potential upside of 44.93%. Given Cronos Group's higher probable upside, research analysts clearly believe Cronos Group is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is CRON or CGC more profitable? Cronos Group has a net margin of -42.65% compared to Canopy Growth's net margin of -156.98%. Cronos Group's return on equity of -2.56% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group-42.65% -2.56% -2.47% Canopy Growth -156.98%-56.52%-24.18% Which has more volatility & risk, CRON or CGC? Cronos Group has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Does the media refer more to CRON or CGC? In the previous week, Canopy Growth had 19 more articles in the media than Cronos Group. MarketBeat recorded 22 mentions for Canopy Growth and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.35 beat Canopy Growth's score of 0.02 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 0 Very Positive mention(s) 0 Positive mention(s) 18 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in CRON or CGC? 8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by insiders. Comparatively, 1.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, CRON or CGC? Cronos Group has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.62M6.16-$73.96M$0.1018.80Canopy Growth$276.75M0.92-$487.23M-$3.80-0.36 SummaryCronos Group beats Canopy Growth on 13 of the 17 factors compared between the two stocks. Get Canopy Growth News Delivered to You Automatically Sign up to receive the latest news and ratings for CGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGC vs. The Competition Export to ExcelMetricCanopy GrowthMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.73M$1.19B$5.57B$7.83BDividend YieldN/AN/A5.11%4.22%P/E Ratio-0.3610.4522.4418.48Price / Sales0.9210.33394.10103.91Price / CashN/A10.4038.1834.62Price / Book0.511.456.774.25Net Income-$487.23M-$54.34M$3.22B$248.23M7 Day Performance11.29%11.77%3.25%3.29%1 Month Performance40.02%22.62%0.01%2.42%1 Year Performance-90.73%-38.98%18.00%5.54% Canopy Growth Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGCCanopy Growth2.5021 of 5 stars$1.38-0.7%$2.00+44.9%-90.7%$253.73M$276.75M-0.363,150Gap DownHigh Trading VolumeCRONCronos Group1.5122 of 5 stars$1.72-3.1%$3.50+104.1%-36.1%$660.97M$117.62M-13.19450DNTHDianthus Therapeutics1.6053 of 5 stars$20.46+4.9%$54.33+165.6%+2.3%$657.30M$6.24M-8.1880News CoveragePositive NewsAVBPArriVent BioPharma1.0013 of 5 stars$19.31+6.4%$39.00+102.0%+28.7%$656.85MN/A-7.5140Short Interest ↑Positive NewsEOLSEvolus3.8685 of 5 stars$10.31-4.4%$23.75+130.4%-3.1%$655.58M$266.27M-11.33170Upcoming EarningsNews CoverageANABAnaptysBio2.4498 of 5 stars$20.70+0.7%$33.63+62.4%-8.7%$634.81M$91.28M-3.40100Upcoming EarningsPositive NewsABUSArbutus Biopharma1.9851 of 5 stars$3.26+3.5%$5.50+68.7%+30.0%$624.23M$6.17M-7.5890Upcoming EarningsPositive NewsXERSXeris Biopharma3.5957 of 5 stars$3.99-2.9%$6.10+52.9%+161.1%$614.22M$203.07M-8.87290Upcoming EarningsPositive NewsCDXCChromaDex2.3362 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastKALVKalVista Pharmaceuticals4.3533 of 5 stars$12.22+1.8%$24.83+103.2%+21.3%$607.53MN/A-3.36100Positive NewsARVNArvinas3.0538 of 5 stars$8.76+1.9%$34.33+291.9%-69.7%$602.44M$263.40M-3.16420Upcoming EarningsShort Interest ↑News Coverage Related Companies and Tools Related Companies CRON Competitors DNTH Competitors AVBP Competitors EOLS Competitors ANAB Competitors ABUS Competitors XERS Competitors CDXC Competitors KALV Competitors ARVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Canopy Growth Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Canopy Growth With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CGC Stock Free CGC Stock Alerts